CLVS goodness...massive blood today...look at monthly....amazing...guess everyone thinks a massive pipeline of cancer treating drugs costing $400 million per year to develop with revenues of $160 million and growing with one FDA approved drug from 2020 Rubraca is unsustainable...and a CEO that has built and sold for $ here and doing it again imo. $200,000,000 shelf going into 2021 with plenty $ in bank.
Bring me the $5.50's tomorrow you hostile takeover drive the share price down takeover artisians.
Hey!, let's take the scenic route artists! So, I can keep adding into the $2's.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.